Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 270 entries
View as:

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03530397 Org: User:
Start: 04/24/18 End: 12/30/25 Due: 12/30/26

Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk

Phase: N/A Priority: Normal
NCT ID: NCT00192439 Org: User:
Start: 12/31/03 End: 12/31/06 Due: 12/31/07

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Phase: N/A Priority: Normal
NCT ID: NCT02088112 Org: User:
Start: 03/24/14 End: 03/09/21 Due: 03/09/22

A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

Phase: N/A Priority: Normal
NCT ID: NCT03385369 Org: User:
Start: 01/05/18 End: 04/12/18 Due: 04/12/19

A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT00677820 Org: User:
Start: 06/30/08 End: 12/31/08 Due: 12/31/09

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT00192127 Org: User:
Start: 08/31/04 End: 02/28/05 Due: 02/28/06

Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382

Phase: N/A Priority: Normal
NCT ID: NCT03347968 Org: User:
Start: 11/27/17 End: 04/09/18 Due: 04/09/19

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00192452 Org: User:
Start: 03/31/01 End: 12/31/01 Due: 12/31/02

Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)

Phase: N/A Priority: Normal
NCT ID: NCT00192361 Org: User:
Start: 11/30/99 End: - Due: -

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01769417 Org: User:
Start: 01/31/13 End: 05/31/14 Due: 05/31/15

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT02503774 Org: User:
Start: 07/24/15 End: 03/07/23 Due: 03/07/24

Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00263783 Org: User:
Start: 03/31/01 End: 06/30/02 Due: 06/30/03

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01352884 Org: User:
Start: 03/31/11 End: 01/31/14 Due: 01/31/15

Assessing Choice in the Employer Setting (ACES) Study

Phase: N/A Priority: Normal
NCT ID: NCT00808808 Org: User:
Start: 09/30/08 End: 12/31/08 Due: 12/31/09

Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT00806728 Org: User:
Start: 05/31/98 End: 12/31/98 Due: 12/31/99

A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT02548585 Org: User:
Start: 12/09/15 End: 02/24/17 Due: 02/24/18

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

Phase: N/A Priority: Normal
NCT ID: NCT00111579 Org: User:
Start: 05/31/05 End: 01/31/06 Due: 01/31/07

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00586924 Org: User:
Start: 05/10/07 End: 05/06/15 Due: 05/06/16

Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.

Phase: N/A Priority: Normal
NCT ID: NCT00192426 Org: User:
Start: 09/30/01 End: 12/31/01 Due: 12/31/02

Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00192296 Org: User:
Start: 08/31/04 End: 03/31/05 Due: 03/31/06

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT04261075 Org: User:
Start: 03/03/20 End: 06/16/22 Due: 06/16/23

CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00659425 Org: User:
Start: 09/30/08 End: 12/31/14 Due: 12/31/15

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

Phase: N/A Priority: Normal
NCT ID: NCT00116168 Org: User:
Start: 06/30/05 End: 07/31/06 Due: 07/31/07

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02340975 Org: User:
Start: 03/31/15 End: 04/29/19 Due: 04/29/20

Respiratory Events Among Premature Infants

Phase: N/A Priority: Normal
NCT ID: NCT00889070 Org: User:
Start: 11/30/08 End: 05/31/09 Due: 05/31/10